Jennerex Therapeutics

Jennerex Therapeutics was a clinical-stage biopharmaceutical company focused on the development of first-in-class oncolytic immunotherapy products for cancer. The company's lead product candidate, Pexa-Vec (JX-594), is an engineered oncolytic virus designed to selectively target and destroy cancer cells through multiple mechanisms, including direct viral lysis and the induction of a systemic anti-tumor immune response. Jennerex utilized its proprietary SOLVE platform to engineer viruses that can be delivered systemically to treat both primary tumors and metastatic disease. In 2014, the company was acquired by SillaJen, a South Korean biotech firm, to further the global development of its oncolytic virus pipeline. The acquisition was valued at approximately $147.5 million, including upfront payments and potential milestones.